Some highlights from the current issue:
From the Editor: Busy time for Actavis
Canada: Orbus to sell its cephalosporin manufacturing facility
USA: Mylan announces third quarter and nine month results
USA: Watson reports third quarter 2008 results
USA: Barr initiates oxybutynin transdermal system patent challenge
USA: Justice Department seeks permanent injunction against Actavis
USA: Hi-Tech gains final dorzolamide approval; Prasco also launches
USA: Sun gains carbidopa and levodopa approval
France: Actavis formally launches
Hungary: Egis reports fourth quarter and fiscal year results
Serbia: Actavis launches atorvastatin
UK: Actavis launches azithromycin product
Japan: ASKA Pharmaceutical and Actavis enter alliance and joint venture
India: Aurobindo reports second quarter results
India: Strides Arcolab announces second quarter results
India: Zydus Cadila gains WHO accreditation for rabies vaccine
Israel: Teva reports third quarter and nine month results

Some highlights from the current issue:
CBO issues report on impact of biosimilars
House Committee releases responses to biosimilar questionnaire
Indian government proposes new biologic regulatory body
UK releases prescription data for England in 2007

Partnering in the Global Generics Industry 2008: A guide to companies
Published July 2008
For everyone needing to evaluate the generic industry’s competitive landscape, this new, thoroughly researched 406-page report is an essential business reference.

Opportunities and Challenges for Generic Drugs in Australia
Published March 2008
This report provides a complete assessment of the US$1.43 billion Australian generic pharmaceutical market.

The World Generic Market Report 2008
Published December 2007
This new 2 volume, 700 page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face.

Emerging Opportunities for Inhalation & Nasal Spray Generic Drugs 2008
Published October 2008
This report provides a complete review of the emerging opportunities and operating environment for inhalation and nasal spray drugs. It reviews products currently available generically and assesses the prospects for those durgs losing patent protection over the next ten years.

Biosimilars: A viable market - but when?
Published September 2008
The promise of profits from biosimilars grows greater, but only when a number of significant market, regulatory and clinical hurdles can be overcome. This critical 200-page management report addresses key issues of concern.

Injectable Generic Drugs : Prospects & Opportunities to 2013
Published July 2008
This report will provide industry planners, commercial developers and the investment community with a thorough review of the operating landscape for generic injectables. The report is packed with primary source information and market forecasts, and takes a balanced view of the players and products that will shape this high value market sector.

CNS Generic Drugs: Prospects & Opportunities to 2012
Published April 2008
This important new strategic report from Espicom evaluates the CNS generic drug market and provides detailed assessment and forecast for leading products by value to 2012, patent expiry opportunities to 2015 and competitive evaluation.

The latest business and market news and developments from around the world
Company plans, deals, developments and performance
The operating environments in major generic markets
New generic drug opportunities by therapy & delivery mechanism
A flexible service to suit every need & budget

Patent Information:

Pipeline™ Selector Patent Reports